United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 80 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin sodium extended-release tablets are indicated the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below. category total-c (mg/dl) ldl-c (mg/dl) acceptable < 170 < 110 borderline 170-199 110-129 high ≥ 200 ≥ 130 children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. in patients with clinically evident chd, fluvastatin sodium extended-release tablets are indicated to: fluvastatin sodium

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin capsules are indicated the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below. category total-c (mg/dl) ldl-c (mg/dl) acceptable < 170 < 110 borderline 170-199 110-129 high ≥ 200 ≥ 130 children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. in patients with clinically evident chd, fluvastatin capsules are indicated to: fluvastatin capsules have not been studied in conditions where th

United States - English - NLM (National Library of Medicine)

sandoz inc - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 80 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin sodium capsules, usp and fluvastatin sodium extended-release tablets, usp are indicated the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below. category total-c (mg/dl) ldl-c (mg/dl) acceptable <170 <110 borderline 170-199 110-129 high ≥200 ≥130 children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. in patients with clinically evident chd, fluvastatin sodium capsules, usp and fluvas

United States - English - NLM (National Library of Medicine)

carilion materials management - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin capsules are indicated: the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below. category total-c (mg/dl) ldl-c (mg/dl) acceptable < 170 < 110 borderline 170 to 199 110 to 129 high ≥ 200 ≥ 130 children treated with fluvastatin in adolescence should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. in patients with clinically evident chd, fluvastatin capsules are indicated to: fluvastatin capsules have not been studied in conditions wh

Canada - English - Health Canada

teva canada limited - fluvastatin (fluvastatin sodium) - capsule - 20mg - fluvastatin (fluvastatin sodium) 20mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

teva canada limited - fluvastatin (fluvastatin sodium) - capsule - 40mg - fluvastatin (fluvastatin sodium) 40mg - hmg-coa reductase inhibitors

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin capsules are indicated - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), triglyceride (tg) and apolipoprotein b (apo b) levels, and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib). - as an adjunct to diet to reduce total-c, ldl-c, and apo b levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin 80 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin sodium extended-release tablets are indicated - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), triglyceride (tg) and apolipoprotein b (apo b) levels, and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib). - as an adjunct to diet to reduce total-c, ldl-c, and apo b levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the followi

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - fluvastatin sodium - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - fluvastatin sodium - oral capsule - 20mg